scholarly journals Clinical Impact of Metronomic Oral Combination Chemotherapy with Capecitabine and Cyclophosphamide in Patients with Metastatic Breast Cancer

2017 ◽  
Vol 78 (2) ◽  
pp. 239-245
Author(s):  
Miwa FUJIHARA ◽  
Yuri YOSHIMURA ◽  
Yukiko KAJIWARA ◽  
Mitsuya ITO ◽  
Shoichiro OHTANI
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Combination Chemotherapy ◽  
Metastatic Breast ◽  
Clinical Impact

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

1996 ◽  
Vol 14 (8) ◽  
pp. 2197-2205 ◽  
Author(s):  
P A Greenberg ◽  
G N Hortobagyi ◽  
T L Smith ◽  
L D Ziegler ◽  
D K Frye ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Complete Remission ◽  
Combination Chemotherapy ◽  
Alkylating Agent ◽  
Performance Status ◽  
Metastatic Breast ◽  
Second Primary ◽  
Treatment Protocols

PURPOSE To determine the long-term clinical course of patients with metastatic breast cancer (MBC) who achieved a complete remission with doxorubicin-alkylating agent-containing combination chemotherapy programs. PATIENTS AND METHODS To assess the long-term prognosis of MBC, we reviewed our experience with 1,581 patients treated on consecutive doxorubicin and alkylating agent-containing front-line treatment protocols between 1973 and 1982. Treatment was administered for a maximum duration of 2 years. Characteristics of long-term survivors were evaluated, and hazard rates for progression were calculated. RESULTS From this group, 263 (16.6%) achieved complete responses (CR) and 49 (3.1%) remained in CR for more than 5 years. After a median duration of 191 months, 26 patients remain in first CR, four patients died in CR at times ranging from 118 to 234 months, 18 patients died of breast cancer, and one is alive with metastatic disease. Compared with the overall CR and total patient populations, the long-term CR group had more premenopausal patients, a younger median age, a lower tumor burden, and better performance status. The hazard function shows a substantial drop in risk of progression after approximately 3 years from initiation of therapy. Ten long-term CR patients developed second primary cancers: breast (3), ovary (2), pancreas (1), endometrium (1), colon (1), head and neck (1), and lung (1). CONCLUSION Most patients with MBC treated with systemic therapies have only temporary responses to treatment, but some patients continue in CR following initial treatment. These data show that a small percentage of patients achieve long-term remissions with standard chemotherapy regimens. Remission consolidation strategies are needed.

Treatment of Metastatic Breast Cancer with Cyclophosphamide, Methotrexate, Vincristine and Fluorouracil.

1973 ◽  
Vol 59 (1) ◽  
pp. 11-24 ◽  
Author(s):  
Mario De Lena ◽  
Giuseppe Maria De Palo ◽  
Gianni Bonadonna ◽  
Gianni Beretta ◽  
Emilio Bajetta
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Combination Chemotherapy ◽  
Metastatic Breast ◽  
Great Majority ◽  
Bone Lesions ◽  
Limiting Factor ◽  
Response Table ◽  
Effective Combination ◽  
Number Of Cycles

From November 1970 to June 1972, 55 patients with metastatic breast cancer were treated with a 4-drug combination (cyclophosphamide, Methotrexate, vincristine and fluorouracil) administered intravenously over a 5-day period (table 1). Treatment was repeated after a 2-week interval for the first 3 cycles, then after 4 weeks. Six more patients were incompletely treated but found evaluable for the toxicity study. The great majority of cases (51/55) was pretreated with radiotherapy, hormone and/or chemotherapy (table 3). The overall response rate was 69 %. Complete (CR) plus partial (PR) remissions (> 50 %) were 46 %. From this evaluation bone lesions was arbitrarily not included since recalcification occurs rarely after chemotherapy. The medium duration of CR was 8 months, that of PR 4 months (table 4). The most responsive lesions were those localized in the soft parts (75%) followed by metastases to lung (55%), pleura and liver (40%). Recalcification of bone lesions was observed in 17 % of cases (table 6). The number of cycles required to produce a regression was found proportional to the degree of response, with a mean of 2 cycles to obtain a PR and a mean of 3 cycles to obtain a CR (table 7). The longest regression was seen in patients with lung or liver involvement (table 8). The duration of the free interval was a positively correlated with the type of response (table 9). The dose limiting factor was represented by bone marrow depression which often required a dose attenuation schedule (table 10 and 11). The actuarial analysis of survival curves (fig.1) showed that patients achieving CR+PR lived longer than those with static disease or progression during combination chemotherapy (P < 0.05). It is concluded that combination chemotherapy can prolong the survival of responsive patients with metastatic breast cancer. The most effective combination can be found only through appropriate controlled clinical trials.

Combination chemotherapy with paclitaxel (T) and epirubicin (E) for metastatic breast cancer (MBC): A phase I–II study

1998 ◽  
Vol 34 ◽  
pp. S12-S13
Author(s):  
A. Durando ◽  
O. Alabiso ◽  
R. Bellino ◽  
F. Genta ◽  
D. Katsaros ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Combination Chemotherapy ◽  
Metastatic Breast

Safety and Efficacy of Using a Single Agent or a Phase II Agent Before Instituting Standard Combination Chemotherapy in Previously Untreated Metastatic Breast Cancer Patients: Report of a Randomized Study—Cancer and Leukemia Group B 8642

1999 ◽  
Vol 17 (5) ◽  
pp. 1397-1397 ◽  
Author(s):  
Mary E. Costanza ◽  
Raymond B. Weiss ◽  
I. Craig Henderson ◽  
Larry Norton ◽  
Donald A. Berry ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Combination Chemotherapy ◽  
Single Agent ◽  
Metastatic Breast ◽  
Response Rates ◽  
Breast Cancer Patients ◽  
Safety And Efficacy

PURPOSE: We undertook a prospective, randomized phase III trial to evaluate the safety and efficacy of using a phase II agent before initiating therapy with standard combination chemotherapy in metastatic breast cancer patients. PATIENTS AND METHODS: A total of 365 women with measurable metastatic breast cancer, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either immediate chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) or up to four cycles of one of five sequential cohorts of single-agent drugs: trimetrexate, melphalan, amonafide, carboplatin, or elsamitrucin, followed by CAF. RESULTS: The toxicity of each single agent followed by CAF was comparable to that of CAF alone. The cumulative response rates for the single agent followed by CAF were not statistically different from those of CAF alone (44% v 52%; P = .24). However, in the multivariate analysis, patients with visceral disease had a trend toward lower response rates on the phase II agent plus CAF arm (P = .078). Although survival and response duration also were not statistically significantly different between the two study arms (P = .074 and P = .069, respectively), there was a suggestion of benefit for the CAF-only arm. CONCLUSION: The brief use of a phase II agent, regardless of its efficacy, followed by CAF resulted in response rates, toxicities, durations of response, and survival statistically equivalent to those seen with the use of CAF alone. These findings support the use of a new paradigm for the evaluation of phase II agents in the treatment of patients with metastatic breast cancer.

Sign in / Sign up

Export Citation Format

Share Document